MarketPulse

clinical development

34 articles
BenzingaBenzinga··Prnewswire

Psychedelic Drug Developers Entering Final Testing Phase for Mental Health Treatments

Five biotech firms advance psychedelic therapies to Phase 3 trials for depression and anxiety, with multiple readouts expected in 2026, marking progress toward regulatory approval.
ATAIDFTXGHRSLBRXpsychedelic biotechnologyPhase 3 trials
BenzingaBenzinga··Prnewswire

Psilocybin Pipeline Expands as Regulatory Support Strengthens for CNS Applications

Psilocybin gains regulatory momentum with first Phase 3 success in treatment-resistant depression. DEA increases production quota 67%, while five pharma companies advance psychedelic programs across multiple CNS indications.
CMPSRLMDANROAXSMFDA approvalPhase 3 trials
BenzingaBenzinga··Globe Newswire

Tevogen Bio Explores Strategic Acquisition of Clinicus Platform Developer

Tevogen Bio pursues acquisition of Sciometrix to gain Clinicus digital care platform, integrating it with its AI division to expand into healthcare services alongside biotech operations.
TVGNTVGNWacquisitionclinical development
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Juvenescence Advances PAI-1 Program With Phase 1 Success, Expands Leadership Team

Juvenescence completes Phase 1 trial of PAI-1 inhibitor MDI-2517 with positive safety results. Company expands leadership and plans Phase 2 study in late 2026.
PFEbiotechclinical development
GlobeNewswire Inc.GlobeNewswire Inc.··Prime Medicine, Inc.

Prime Medicine to Present at Three Major Biotech Conferences in March

Prime Medicine will present at three major biotech conferences in March 2026, including TD Cowen and Citizens Life Sciences, with webcasts available afterward.
PRMEclinical developmentinvestor conference
BenzingaBenzinga··Vandana Singh

GSK Acquires 35Pharma for $950M to Strengthen Pulmonary Hypertension Portfolio

GSK acquires 35Pharma for $950M, adding pulmonary hypertension treatment HS235 to its pipeline. Move strengthens GSK's position in the growing $18B market.
GSKRAPTacquisitionclinical development
BenzingaBenzinga··Globe Newswire

GSK Acquires 35Pharma for $950M to Advance Pulmonary Hypertension Treatment

GSK acquires 35Pharma for $950M to gain HS235, a clinical-stage pulmonary hypertension drug with improved safety profiles versus existing treatments.
GSKacquisitionclinical development
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Kyverna Bolsters Board With Beam, Karuna Executives Ahead of Cell Therapy Launch

Kyverna appoints two biotech executives to its board ahead of cell therapy commercialization. New directors bring expertise from Beam Therapeutics and Karuna Therapeutics.
BMYCELGrKYTXBEAMclinical developmentautoimmune diseases
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Aclaris Advances Dual-Target Antibody into Asthma Study Following Dermatitis Trial Launch

Aclaris launches Phase 1b asthma trial for ATI-052, a dual-target antibody also in dermatitis trials. Results expected mid-2026.
ACRSclinical developmentatopic dermatitis
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Starton Advances Subcutaneous Lenalidomide Program With Phase 2a Multiple Myeloma Trial Launch

Starton launches Phase 2a trial for subcutaneous lenalidomide delivery in multiple myeloma, comparing three dose levels against standard oral Revlimid treatment.
BMYCELGrclinical developmentmultiple myeloma
BenzingaBenzinga··Globe Newswire

Coherus Oncology Raises $50.1M in Stock Offering to Fund Oncology Pipeline

Coherus Oncology raised $50.1M through stock offering to fund commercial launch of LOQTORZI and advance its oncology pipeline development.
CHRSclinical developmentpublic offering
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Artios Pharma Bolsters Executive Ranks Ahead of Late-Stage Oncology Trials

Artios Pharma appoints three senior executives to strengthen manufacturing, clinical operations, and medical affairs as it advances late-stage oncology trials.
LLYJAZZFDA approvalclinical development
GlobeNewswire Inc.GlobeNewswire Inc.··Okyo Pharma Limited

OKYO Pharma Prices $20M Share Offering to Fund Clinical Development

OKYO Pharma prices $20M share offering to fund clinical development of urcosimod for neuropathic corneal pain treatment, advancing Phase 2b/3 trial.
OKYOPIPRclinical developmentpublic offering
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Coherus Oncology Raises $50.1M Through Common Stock Offering

Coherus Oncology raises $50.1M via stock offering to fund commercial expansion of LOQTORZI and advance oncology pipeline development programs.
CHRSclinical developmentpublic offering